Stefanik D F, Fellows W K, Rizkalla L R, Rizkalla W M, Stefanik P P, Deleo A B, Welch W C
Department of Radiation Oncology, Conemaugh Memorial Medical Center, Johnstown, PA, USA.
J Neurooncol. 2001 Nov;55(2):91-100. doi: 10.1023/a:1013329832067.
Monoclonal antibodies raised to peptide sequences of vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibited the growth of C6 tumors growing subcutaneously in nude mice. Immunohistochemical analysis demonstrated antibody targeting of blood vessels, tumor cells, and macrophages. A control antibody demonstrated no growth inhibition or tumor uptake. An antibody to FLT- I impaired microvascular maturation and diminished the accumulation of tumor infiltrating macrophages. The antibodies demonstrated affinity for microvasculature and tumor cells in immunohistochemistry of human glioblastoma multiforme. Targeting VEGF and its receptors has potential in the treatment of tumors of the central nervous system. FLT-1 presents an attractive target due to its presence on multiple cell types.
针对血管内皮生长因子(VEGF)和VEGF受体FLT-1的肽序列产生的单克隆抗体,抑制了裸鼠皮下生长的C6肿瘤的生长。免疫组织化学分析表明抗体靶向血管、肿瘤细胞和巨噬细胞。对照抗体未显示出生长抑制或肿瘤摄取。一种针对FLT-1的抗体损害了微血管成熟,并减少了肿瘤浸润巨噬细胞的积聚。在多形性胶质母细胞瘤的免疫组织化学中,这些抗体显示出对微血管和肿瘤细胞的亲和力。靶向VEGF及其受体在中枢神经系统肿瘤的治疗中具有潜力。由于FLT-1存在于多种细胞类型上,它是一个有吸引力的靶点。